Last reviewed · How we verify
Morphine p.o.
Morphine binds to opioid receptors in the central nervous system to reduce pain perception and produce analgesia.
Morphine binds to opioid receptors in the central nervous system to reduce pain perception and produce analgesia. Used for Moderate to severe acute pain, Moderate to severe chronic pain, Cancer pain.
At a glance
| Generic name | Morphine p.o. |
|---|---|
| Sponsor | Brigham and Women's Hospital |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Morphine is a mu-opioid receptor agonist that crosses the blood-brain barrier and acts on opioid receptors in the brain and spinal cord. This binding modulates pain signal transmission and produces analgesic, sedative, and euphoric effects. It is one of the oldest and most widely used opioid analgesics for moderate to severe pain management.
Approved indications
- Moderate to severe acute pain
- Moderate to severe chronic pain
- Cancer pain
- Postoperative pain
Common side effects
- Constipation
- Nausea
- Drowsiness
- Dizziness
- Vomiting
- Respiratory depression
- Dependence and tolerance
Key clinical trials
- Impacts of Opioids on Respiratory Drive During Sleep (EARLY_PHASE1)
- Effect of Combinations of Paracetamol, Ibuprofen, and Dexamethasone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty (PHASE4)
- Pregabalin Versus Gabapentin Opioid Sparing Effect in Discectomy (PHASE3)
- Effects of Dexmedetomidine on Cognitive Outcome and Brain Injury Markers (NA)
- Aprepitant Effects on Oxycodone Response (NA)
- Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio) (PHASE3)
- The German Project of Heroin Assisted Treatment of Opiate Dependent Patients (PHASE3)
- Controlled-Release Oxycodone For Postoperative Analgesia After Video-Assisted Thoracic Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Morphine p.o. CI brief — competitive landscape report
- Morphine p.o. updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI